June 17, 2016—The Health Resources and Services Administration has sent its proposed rule to create a mandatory and binding administrative dispute resolution process for the 340B program to the White House for pre-publication review. … [Read more...]
340B Recertification for Hospitals Tentatively to Begin on Aug. 10
Informational webinar penciled in for July 20June 16, 2016—The Health Resources and Services Administration has started informing hospital groups that annual recertification of eligibility for 340B drug discounts for hospitals is tentatively scheduled to begin Aug. 10 and end Sept. 7, with an informational webinar currently set for July 20. … [Read more...]
OIG Issues Report on Excluding 340B Drugs from Medicaid MCO Rebates
Recommends using claim-level methods to identify claims for 340B-purchased drugsJune 14, 2016—A new Department of Health and Human Services Office of Inspector General analysis of the ways states identify 340B drugs given to Medicaid managed care organization patients concludes that claim-level methods "can help states more accurately identify 340B claims, and thus reduce the risk of duplicate discounts and foregone rebates associated with … [Read more...]
Senate Appropriators Vote to Level-Fund 340B
Committee includes 0.1 percent user feeJune 10, 2016—Senate appropriators voted yesterday to level-fund the 340B program at $10.24 million in fiscal year 2017, which begins Oct. 1. … [Read more...]
Senators Want Answers About Overdose Rescue Drug’s Rising Cost
Pfizer and Mylan among drugmakers under scrutinyJune 8, 2016—A Senate committee investigating sky-high pricing on age-old medicines wants five drugmakers to explain why an opioid overdose rescue drug's cost is rising. … [Read more...]
Vermont Enacts Drug Price Transparency Law
Measure also addresses Medicaid dispensing fee for 340B drugsJune 6, 2016—Vermont Gov. Peter Shumlin has signed a bill into law requiring makers of prescription drugs with rapidly escalating prices to document and justify the increases. Failure to comply could lead to a $10,000 civil penalty. … [Read more...]
Stakeholders Comment Again on 340B Pricing and Manufacturer Penalty Regulation
Providers and industry spar over penny pricingMay 26, 2016—Sixty-nine stakeholders have submitted comments online to the Health Resources and Services Administration about its proposed rule setting standards for calculating 340B ceiling prices and implementing civil monetary penalties for drugmakers that knowingly and intentionally overcharge for 340B drugs. The drug industry is adamant that HRSA drop its 340B penny … [Read more...]